Human Antibodies Identified That Have Potential To Prevent and Treat Measles Virus

Why It Matters

The discovery provides a potential treatment option for immunocompromised and unvaccinated populations, addressing a critical gap in measles care as herd immunity wanes.

Key Takeaways

• First human monoclonal antibodies neutralizing measles identified
• Antibodies target hemagglutinin and fusion proteins, blocking entry
• Cotton‑rat studies showed up to 500‑fold viral load reduction
• Antibody 3A12 made circulating virus undetectable after exposure
• Four non‑competing mAbs could form a cocktail to prevent escape

Pulse Analysis

Measles cases have surged in recent years as vaccination coverage slips, leaving infants, pregnant women and immunocompromised patients vulnerable. While the live‑attenuated MMR vaccine remains the gold standard, it cannot be administered to those with weakened immune systems, creating a therapeutic void. The new human monoclonal antibodies (mAbs) from La Jolla Institute aim to fill that gap, offering both pre‑exposure prophylaxis and post‑exposure treatment for the most at‑risk groups.

The research team used cryo‑electron microscopy to map how the antibodies latch onto two critical surface proteins—hemagglutinin (H) and fusion (F). These mAbs demonstrated potency two orders of magnitude greater than previously reported candidates. In a cotton‑rat model, all four lead antibodies lowered viral loads dramatically, with one (3A12) completely clearing detectable virus. The antibodies lock the fusion protein in a static conformation, preventing the shape‑shifting step essential for viral entry. Such mechanistic insight accelerates the path toward a clinically viable antibody cocktail.

If advanced to human trials, these antibodies could become the first FDA‑approved measles therapy, complementing vaccination campaigns and protecting those who cannot be vaccinated. The cocktail approach—combining four non‑competing epitopes—reduces the risk of viral escape and may extend protection across all 24 circulating genotypes. Biotech firms are likely to pursue rapid development, leveraging existing mAb production platforms used for RSV and COVID‑19, positioning the market for a high‑value, life‑saving product in a disease that continues to threaten public health.